<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37122293</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Cognitive inhibition deficit in long COVID-19: An exploratory study.</ArticleTitle><Pagination><StartPage>1125574</StartPage><MedlinePgn>1125574</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1125574</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2023.1125574</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="UNASSIGNED">An increasing number of research studies point toward the importance and prevalence of long-term neurocognitive symptoms following infection with COVID-19. Our objectives were to capture the prevalence of cognitive impairments from 1 to 16&#x2009;months post-COVID-19 infection, assess the changes in neuropsychological functions over time, and identify factors that can predict long-term deficits in cognition.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="UNASSIGNED">A cross-sectional research design was adopted to compare four sub-samples recruited over a 16-month timeframe (1-4, 5-8, 9-12, and 13-16&#x2009;months). Phone interviews were conducted at least 6&#x2009;weeks after being infected by COVID-19. Sociodemographic and clinical questionnaires were administered followed by standardized neurocognitive and psychological tests and health questionnaires screening cognitive symptoms, anxiety, depression, fatigue, and autonomy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Regarding general health questionnaires, 55.2% of the 134 participants had symptoms of psychiatric illness, while 21.6% of patients had moderate-to-severe anxiety or depression. Cognitive efficiency was diminished in 19.4% of our population. Executive dysfunction was screened in 56% of patients, and an impairment of cognitive flexibility and inhibition was revealed in 38.8%. Depression, hospital or intensive care unit (ICU) admission, and the duration of hospital or ICU stay were associated with an inhibition deficit. The duration elapsed from the initial infection, and the neurocognitive assessment was not associated with a decrease in inhibition deficit. The prevalence of cognitive impairments, other than inhibition deficit, tended to decrease during the study period.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">This study supports the extensive literature on the cognitive and neuropsychiatric sequelae of COVID-19 and highlights long-lasting inhibition deficits, while other cognitive functions seemed to improve over time. The severity of infection could interact as a catalyst in the complex interplay between depression and executive functions. The absence of a relation between inhibition deficits and sociodemographic or medical factors reinforces the need for cognitive screening in all COVID-19 patients. Future research should focus on inhibition deficits longitudinally to assess the progression of this impairment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Saucier, Jose, Beroual, Al-Qadi, Chartrand, Libert, Losier, Cooling, Girouard, Jbilou and Chamard-Witkowski.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saucier</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jose</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vitality Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beroual</LastName><ForeName>Zaynab</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Qadi</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chartrand</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libert</LastName><ForeName>Em&#xe9;raldine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losier</LastName><ForeName>Marie-Claire</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Vitality Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooling</LastName><ForeName>Kendra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vitality Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girouard</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vitality Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jbilou</LastName><ForeName>Jalila</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychology, Universit&#xe9; de Moncton, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamard-Witkowski</LastName><ForeName>Ludivine</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine et des Sciences de la Sant&#xe9;, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center de Formation M&#xe9;dicale du Nouveau-Brunswick, Moncton, NB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vitality Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">executive syndrome</Keyword><Keyword MajorTopicYN="N">inhibition</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">psychological outcomes</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>3</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37122293</ArticleId><ArticleId IdType="pmc">PMC10140516</ArticleId><ArticleId IdType="doi">10.3389/fneur.2023.1125574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. . Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. (2020) 7:611&#x2013;27. doi: 10.1016/S2215-0366(20)30203-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;ndez R, Balanz&#xe1;-Mart&#xed;nez V, Luperdi SC, Estrada I, Latorre A, Gonz&#xe1;lez-Jim&#xe9;nez P, et al. . Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. (2021) 290:621&#x2013;31. doi: 10.1111/joim.13262, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13262</ArticleId><ArticleId IdType="pmc">PMC8013333</ArticleId><ArticleId IdType="pubmed">33533521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. . Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain J Neurol. (2021) 144:1263&#x2013;76. doi: 10.1093/brain/awab009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab009</ArticleId><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ermis U, Rust MI, Bungenberg J, Costa A, Dreher M, Balfanz P, et al. . Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurol Res Pract. (2021) 3:17. doi: 10.1186/s42466-021-00116-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42466-021-00116-1</ArticleId><ArticleId IdType="pmc">PMC7953515</ArticleId><ArticleId IdType="pubmed">33712089</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J, et al. . Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. (2021) 46:39&#x2013;48. doi: 10.1016/j.euroneuro.2021.03.019, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2021.03.019</ArticleId><ArticleId IdType="pmc">PMC8006192</ArticleId><ArticleId IdType="pubmed">33823427</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-S&#xe1;nchez C, Calabria M, Grunden N, Pons C, Arroyo JA, G&#xf3;mez-Anson B, et al. . Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain Behav. (2022) 12:e2508. doi: 10.1002/brb3.2508</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.2508</ArticleId><ArticleId IdType="pmc">PMC8933779</ArticleId><ArticleId IdType="pubmed">35137561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchetti G, Agosta F, Canu E, Basaia S, Barbieri A, Cardamone R, et al. . Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. J Neurol. (2022) 269:3400&#x2013;12. doi: 10.1007/s00415-022-11047-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11047-5</ArticleId><ArticleId IdType="pmc">PMC8898558</ArticleId><ArticleId IdType="pubmed">35249144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattioli F, Stampatori C, Righetti F, Sala E, Tomasi C, De Palma G. Neurological and cognitive sequelae of Covid-19: a four month follow-up. J Neurol. (2021) 268:4422&#x2013;8. doi: 10.1007/s00415-021-10579-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10579-6</ArticleId><ArticleId IdType="pmc">PMC8088203</ArticleId><ArticleId IdType="pubmed">33932157</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, et al. . Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. (2021) 94:138&#x2013;47. doi: 10.1016/j.bbi.2021.02.021, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.02.021</ArticleId><ArticleId IdType="pmc">PMC7903920</ArticleId><ArticleId IdType="pubmed">33639239</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE  Overview|COVID-19 rapid guideline: Managing the long-term effects of COVID-19|guidance|NICE [internet]. NICE. (2022). Available at: https://www.nice.org.uk/guidance/ng188 (Accessed July 15, 2022).</Citation></Reference><Reference><Citation>Crivelli L, Calandri I, Corval&#xe1;n N, Carello MA, Keller G, Mart&#xed;nez C, et al. . Cognitive consequences of COVID-19: results of a cohort study from South America. Arq Neuropsiquiatr. (2022) 80:240&#x2013;7. doi: 10.1590/0004-282x-anp-2021-0320, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0004-282x-anp-2021-0320</ArticleId><ArticleId IdType="pmc">PMC9648931</ArticleId><ArticleId IdType="pubmed">34816972</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. (2020) 9:100163. doi: 10.1016/j.bbih.2020.100163, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100163</ArticleId><ArticleId IdType="pmc">PMC7581383</ArticleId><ArticleId IdType="pubmed">33111132</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. . Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open. (2021) 4:e2130645. doi: 10.1001/jamanetworkopen.2021.30645, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30645</ArticleId><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, et al. . Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. (2022) 4:fcab297. doi: 10.1093/braincomms/fcab297, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab297</ArticleId><ArticleId IdType="pmc">PMC8833580</ArticleId><ArticleId IdType="pubmed">35169700</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattioli F, Piva S, Stampatori C, Righetti F, Mega I, Peli E, et al. . Neurologic and cognitive sequelae after SARS-CoV2 infection: different impairment for ICU patients. J Neurol Sci. (2022) 432:120061. doi: 10.1016/j.jns.2021.120061, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.120061</ArticleId><ArticleId IdType="pmc">PMC8620095</ArticleId><ArticleId IdType="pubmed">34894422</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannorsdall TD, Brigham E, Fawzy A, Raju S, Gorgone A, Pletnikova A, et al. . Cognitive dysfunction, psychiatric distress, and functional decline after COVID-19. J Acad Consult Liaison Psychiatry. (2022) 63:133&#x2013;43. doi: 10.1016/j.jaclp.2021.10.006, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaclp.2021.10.006</ArticleId><ArticleId IdType="pmc">PMC8591857</ArticleId><ArticleId IdType="pubmed">34793996</ArticleId></ArticleIdList></Reference><Reference><Citation>Henneghan AM, Lewis KA, Gill E, Kesler SR. Cognitive impairment in non-critical, mild-to-moderate COVID-19 survivors. Front Psychol. (2022) 13:770459. doi: 10.3389/fpsyg.2022.770459, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2022.770459</ArticleId><ArticleId IdType="pmc">PMC8891805</ArticleId><ArticleId IdType="pubmed">35250714</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond A. Executive functions. Annu Rev Psychol. (2013) 64:135&#x2013;68. doi: 10.1146/annurev-psych-113011-143750, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-psych-113011-143750</ArticleId><ArticleId IdType="pmc">PMC4084861</ArticleId><ArticleId IdType="pubmed">23020641</ArticleId></ArticleIdList></Reference><Reference><Citation>Joormann J, Yoon KL, Zetsche U. Cognitive inhibition in depression. Appl Prev Psychol. (2007) 12:128&#x2013;39. doi: 10.1016/j.appsy.2007.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.appsy.2007.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin EA, Cicero DC, Kerns JG. Social anhedonia, but not positive schizotypy, is associated with poor affective control. Pers Disord. (2012) 3:263&#x2013;72. doi: 10.1037/a0024488</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0024488</ArticleId><ArticleId IdType="pubmed">22452767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortelli P, Ferrazzoli D, Sebastianelli L, Engl M, Romanello R, Nardone R, et al. . Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: insights into a challenging symptom. J Neurol Sci. (2021) 420:117271. doi: 10.1016/j.jns.2020.117271, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117271</ArticleId><ArticleId IdType="pmc">PMC7834526</ArticleId><ArticleId IdType="pubmed">33359928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortelli P, Ferrazzoli D, Sebastianelli L, Maestri R, Dezi S, Spampinato D, et al. . Altered motor cortex physiology and dysexecutive syndrome in patients with fatigue and cognitive difficulties after mild COVID-19. Eur J Neurol. (2022) 29:1652&#x2013;62. doi: 10.1111/ene.15278, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15278</ArticleId><ArticleId IdType="pmc">PMC9111319</ArticleId><ArticleId IdType="pubmed">35138693</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Chen R, Liu X, Zhao G, Zheng Y, Gong M, et al. . The impairing effects of mental fatigue on response inhibition: an ERP study. PLoS One. (2018) 13:e0198206. doi: 10.1371/journal.pone.0198206, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0198206</ArticleId><ArticleId IdType="pmc">PMC5983454</ArticleId><ArticleId IdType="pubmed">29856827</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T. Neurological infection with SARS-CoV-2&#x2014;the story so far. Nat Rev Neurol. (2021) 17:65&#x2013;6. doi: 10.1038/s41582-020-00453-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00453-w</ArticleId><ArticleId IdType="pmc">PMC7789883</ArticleId><ArticleId IdType="pubmed">33414554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs. (2022) 36:681&#x2013;702. doi: 10.1007/s40263-022-00931-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-022-00931-3</ArticleId><ArticleId IdType="pmc">PMC9210800</ArticleId><ArticleId IdType="pubmed">35727534</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva LL, Silva RO, de Sousa LG, de Ara&#xfa;jo Costa AC, Barros DF, Silva-N&#xe9;to RP. Is there a common pathophysiological mechanism between COVID-19 and depression? Acta Neurol Belg. (2021) 121:1117&#x2013;22. doi: 10.1007/s13760-021-01748-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-021-01748-5</ArticleId><ArticleId IdType="pmc">PMC8321009</ArticleId><ArticleId IdType="pubmed">34327666</ArticleId></ArticleIdList></Reference><Reference><Citation>Albornoz EA, Amarilla AA, Modhiran N, Parker S, Li XX, Wijesundara DK, et al. . SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. (2022) 1&#x2013;16. doi: 10.1038/s41380-022-01831-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01831-0</ArticleId><ArticleId IdType="pmc">PMC10615762</ArticleId><ArticleId IdType="pubmed">36316366</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiat. (2021) 78:682&#x2013;3. doi: 10.1001/jamapsychiatry.2021.0500, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.0500</ArticleId><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. . Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. (2021) 24:168&#x2013;75. doi: 10.1038/s41593-020-00758-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J, Lampe J, M&#xfc;ller-Fielitz H, Schuster R, Zille M, M&#xfc;ller K, et al. . The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci. (2021) 24:1522&#x2013;33. doi: 10.1038/s41593-021-00926-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00926-1</ArticleId><ArticleId IdType="pmc">PMC8553622</ArticleId><ArticleId IdType="pubmed">34675436</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, et al. . SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. (2021) 6:337. doi: 10.1038/s41392-021-00719-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00719-9</ArticleId><ArticleId IdType="pmc">PMC8419672</ArticleId><ArticleId IdType="pubmed">34489403</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuovo GJ, Magro C, Shaffer T, Awad H, Suster D, Mikhail S, et al. . Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. Ann Diagn Pathol. (2021) 51:151682. doi: 10.1016/j.anndiagpath.2020.151682, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anndiagpath.2020.151682</ArticleId><ArticleId IdType="pmc">PMC7758180</ArticleId><ArticleId IdType="pubmed">33360731</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L, Albecka A, Mallery DL, Kellner MJ, Paul D, Carter AP, et al. . SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain Organoids. Cell Stem Cell. (2020) 27:951&#x2013;961.e5. doi: 10.1016/j.stem.2020.10.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7553118</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob F, Pather SR, Huang WK, Zhang F, Wong SZH, Zhou H, et al. . Human pluripotent stem cell-derived neural cells and brain Organoids reveal SARS-CoV-2 Neurotropism predominates in choroid plexus epithelium. Cell Stem Cell. (2020) 27:937&#x2013;950.e9. doi: 10.1016/j.stem.2020.09.016, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7505550</ArticleId><ArticleId IdType="pubmed">33010822</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcioglu YH, Yesilkaya UH, Gokcay H, Kirlioglu SS. May the central nervous system be fogged by the cytokine storm in COVID-19?: an appraisal. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. (2020) 15:343&#x2013;4. doi: 10.1007/s11481-020-09932-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-020-09932-9</ArticleId><ArticleId IdType="pmc">PMC7287281</ArticleId><ArticleId IdType="pubmed">32529462</ArticleId></ArticleIdList></Reference><Reference><Citation>Thye AYK, Law JWF, Tan LTH, Pusparajah P, Ser HL, Thurairajasingam S, et al. . Psychological symptoms in COVID-19 patients: insights into pathophysiology and risk factors of long COVID-19. Biology. (2022) 11:61. doi: 10.3390/biology11010061, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology11010061</ArticleId><ArticleId IdType="pmc">PMC8773222</ArticleId><ArticleId IdType="pubmed">35053059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, et al. . Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cells. (2022) 185:2452&#x2013;2468.e16. doi: 10.1016/j.cell.2022.06.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Soung A, Sissoko C, Nordvig A, Canoll P, Mariani M, et al. . COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis. Research Square [Preprint]. (2021) doi: 10.21203/rs.3.rs-1031824/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1031824/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YH, Chen Y, Wang QH, Wang LR, Jiang L, Yang Y, et al. . One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol. (2022) 79:509&#x2013;17. doi: 10.1001/jamaneurol.2022.0461, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.0461</ArticleId><ArticleId IdType="pmc">PMC8905512</ArticleId><ArticleId IdType="pubmed">35258587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rass V, Beer R, Schiefecker AJ, Lindner A, Kofler M, Ianosi BA, et al. . Neurological outcomes 1 year after COVID-19 diagnosis: a prospective longitudinal cohort study. Eur J Neurol. (2022) 29:1685&#x2013;96. doi: 10.1111/ene.15307, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15307</ArticleId><ArticleId IdType="pmc">PMC9111823</ArticleId><ArticleId IdType="pubmed">35239247</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Brutto OH, Rumbea DA, Recalde BY, Mera RM. Cognitive sequelae of long COVID may not be permanent: a prospective study. Eur J Neurol. (2022) 29:1218&#x2013;21. doi: 10.1111/ene.15215</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15215</ArticleId><ArticleId IdType="pubmed">34918425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza M, Cano N, Segura B, Adan A, Bargall&#xf3; N, Cald&#xfa; X, et al. . Neuropsychological impairment in post-COVID condition individuals with and without cognitive complaints. Front Aging Neurosci. (2022) 14:1029842. doi: 10.3389/fnagi.2022.1029842, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.1029842</ArticleId><ArticleId IdType="pmc">PMC9631485</ArticleId><ArticleId IdType="pubmed">36337708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. (2001) 16:606&#x2013;13. doi: 10.1046/j.1525-1497.2001.016009606.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L&#xf6;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. (2006) 166:1092&#x2013;7. doi: 10.1001/archinte.166.10.1092</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. The Gerontologist. (1969) 9:179&#x2013;86. doi: 10.1093/geront/9.3_Part_1.179, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/9.3_Part_1.179</ArticleId><ArticleId IdType="pubmed">5349366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. . The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer. (1999) 85:1186&#x2013;96. doi: 10.1002/(SICI)1097-0142(19990301)85:5&lt;1186::AID-CNCR24&gt;3.0.CO;2-N</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0142(19990301)85:5&lt;1186::AID-CNCR24&gt;3.0.CO;2-N</ArticleId><ArticleId IdType="pubmed">10091805</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Roberts RO, Geda YE, Pankratz VS, Christianson TJH, Petersen RC, et al. . Validation of the telephone interview for cognitive status-modified in subjects with Normal cognition, mild cognitive impairment, or dementia. Neuroepidemiology. (2010) 34:34&#x2013;42. doi: 10.1159/000255464, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000255464</ArticleId><ArticleId IdType="pmc">PMC2857622</ArticleId><ArticleId IdType="pubmed">19893327</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastug G, Ozel-Kizil ET, Sakarya A, Altintas O, Kirici S, Altunoz U. Oral Trail making task as a discriminative tool for different levels of cognitive impairment and Normal aging. Arch Clin Neuropsychol. (2013) 28:411&#x2013;7. doi: 10.1093/arclin/act035, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/arclin/act035</ArticleId><ArticleId IdType="pubmed">23742903</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess PW, Shallice T. The Hayling and Brixton Tests. Bury St Edmunds: Thames Valley Test Company. (1997).</Citation></Reference><Reference><Citation>Bayard S, G&#xe9;ly-Nargeot MC, Raffard S, Guerdoux-Ninot E, Kamara E, Gros-Balthazard F, et al. . French version of the Hayling sentence completion test, part I: normative data and guidelines for error scoring. Arch Clin Neuropsychol Off J Natl Acad Neuropsychol. (2017) 32:585&#x2013;91. doi: 10.1093/arclin/acx010, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/arclin/acx010</ArticleId><ArticleId IdType="pubmed">28168283</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; (1994).</Citation></Reference><Reference><Citation>Fong TG, Fearing MA, Jones RN, Shi P, Marcantonio ER, Rudolph JL, et al. . Telephone interview for cognitive status: creating a crosswalk with the mini-mental state examination. Alzheimers Dement J Alzheimers Assoc. (2009) 5:492&#x2013;7. doi: 10.1016/j.jalz.2009.02.007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2009.02.007</ArticleId><ArticleId IdType="pmc">PMC2783323</ArticleId><ArticleId IdType="pubmed">19647495</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. When to use the Bonferroni correction. Br J Physiol Opt. (2014) 34:502&#x2013;8. doi: 10.1111/opo.12131</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/opo.12131</ArticleId><ArticleId IdType="pubmed">24697967</ArticleId></ArticleIdList></Reference><Reference><Citation>The jamovi project  jamovi (Version 1.6) [Computer Software]. (2021) Available at: https://www.jamovi.org</Citation></Reference><Reference><Citation>Ferrucci R, Dini M, Rosci C, Capozza A, Groppo E, Reitano MR, et al. . One-year cognitive follow-up of COVID-19 hospitalized patients. Eur J Neurol. (2022) 29:2006&#x2013;14. doi: 10.1111/ene.15324, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15324</ArticleId><ArticleId IdType="pmc">PMC9111730</ArticleId><ArticleId IdType="pubmed">35285122</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Yang D, Medicherla C, Baskharoun S, Bauman K, Bell L, et al. . Trajectories of neurologic recovery 12 months after hospitalization for COVID-19: a prospective longitudinal study. Neurology. (2022) 99:e33&#x2013;45. doi: 10.1212/WNL.0000000000200356, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200356</ArticleId><ArticleId IdType="pmc">PMC9259089</ArticleId><ArticleId IdType="pubmed">35314503</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen RF, Robertson DA, Kenny RA, King-Kallimanis BL. Strengths and limitations of the MoCA for assessing cognitive functioning: findings from a large representative sample of Irish older adults. J Geriatr Psychiatry Neurol. (2016) 29:18&#x2013;24. doi: 10.1177/0891988715598236, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988715598236</ArticleId><ArticleId IdType="pubmed">26251108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratcliffe LN, McDonald T, Robinson B, Sass JR, Loring DW, Hewitt KC. Classification statistics of the Montreal cognitive assessment (MoCA): are we interpreting the MoCA correctly? Clin Neuropsychol. (2023) 37:562&#x2013;76. doi: 10.1080/13854046.2022.2086487</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854046.2022.2086487</ArticleId><ArticleId IdType="pmc">PMC10351673</ArticleId><ArticleId IdType="pubmed">35699222</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz MJ, Wang C, Nester CO, Derby CA, Zimmerman ME, Lipton RB, et al. . T-MoCA: a valid phone screen for cognitive impairment in diverse community samples. DADM. (2021) 13:e12144. doi: 10.1002/dad2.12144, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12144</ArticleId><ArticleId IdType="pmc">PMC7864219</ArticleId><ArticleId IdType="pubmed">33598528</ArticleId></ArticleIdList></Reference><Reference><Citation>Costas-Carrera A, S&#xe1;nchez-Rodr&#xed;guez MM, Ca&#xf1;izares S, Ojeda A, Mart&#xed;n-Villalba I, Prim&#xe9;-Tous M, et al. . Neuropsychological functioning in post-ICU patients after severe COVID-19 infection: the role of cognitive reserve. Brain Behav Immun Health. (2022) 21:100425. doi: 10.1016/j.bbih.2022.100425, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100425</ArticleId><ArticleId IdType="pmc">PMC8818554</ArticleId><ArticleId IdType="pubmed">35156065</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry. (2007) 61:198&#x2013;209. doi: 10.1016/j.biopsych.2006.05.048, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2006.05.048</ArticleId><ArticleId IdType="pubmed">17027931</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirau L, Lui F. Frontal Lobe Syndrome [internet]. Treasure Island (FL): StatPearls Publishing; (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">30422576</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. (1935) 18:643&#x2013;62. doi: 10.1037/h0054651</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/h0054651</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. . SARS-CoV-2 is associated with changes in brain structure in UK biobank. Nature. (2022) 604:697&#x2013;707. doi: 10.1038/s41586-022-04569-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. 18FDG PET/CT scan reveals hypoactive orbitofrontal cortex in anosmia of COVID-19. Acad Radiol. (2020) 27:1042&#x2013;3. doi: 10.1016/j.acra.2020.04.030, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2020.04.030</ArticleId><ArticleId IdType="pmc">PMC7196385</ArticleId><ArticleId IdType="pubmed">32386948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocciolillo F, Di Giuda D, Morello R, De Rose C, Valentini P, Buonsenso D. Orbito-frontal cortex Hypometabolism in children with post-COVID condition (long COVID): a preliminary experience. Pediatr Infect Dis J. (2022) 41:663&#x2013;5. doi: 10.1097/INF.0000000000003578, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003578</ArticleId><ArticleId IdType="pmc">PMC9281418</ArticleId><ArticleId IdType="pubmed">35839175</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. . 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. (2021) 48:2823&#x2013;33. doi: 10.1007/s00259-021-05215-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>